Pharmaceutical Peptides Bivalirudin Acetate /Bivalirudin Trifluoroacetate /128270-60-0 CAS NO.149635-73-4
- FOB Price: USD: 15.00-15.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: T/T,Other
- Available Specifications:
pharmaceutical grade(1-1000)Gram
- Product Details
Keywords
- Peptides
- Pharmaceutical Intermediate
- Chemical
Quick Details
- ProName: Pharmaceutical Peptides Bivalirudin Ac...
- CasNo: 149635-73-4
- Molecular Formula: C98h138n24o33
- Appearance: White Powder
- Application: bodybuilding pharmaceutical material, ...
- DeliveryTime: 3days
- PackAge: Packaging can be according to customer
- Port: Shanghai
- ProductionCapacity: 10000 Metric Ton/Day
- Purity: 99%
- Storage: Keep it under seal in cool and dark pl...
- Transportation: FEDEX DHL TNT UPS EUB
- LimitNum: 1 Gram
- Related Substances: Peptides
- Residue on Ignition: 0
- Heavy Metal: 0
- Valid Period: 2years
- CasNo: 128270-60-0
- Molecular Formula: C98h138n24o33
- Appearance: detailed see specifications
- Purity: 99%
- Grade: Grade
- LimitNum: 1 Gram
Superiority
This is Allen from Zhengzhou Filter Biotechnology Co.,Ltd.We are the professional supplier of peptide products in China over 10 years. we have Professional Lab to confirm the Quality and Serive for all clients in long-term run cooperation.
Our Company as a Pharmaceutical Raw Material Manufacturer specialize in R&D the New Drugs and Producing the Generic Medicine:
Amino Acids&Vitamins
Pharmaceutical Polypeptide,
Comestic Polypeptide,
Veterinary Peptide and
Pharmaceutical APIs.
Due to of the high quality and good service, They have been exported more than 30 countries.
Sincerely hope to have a chance to cooperate with you
Details
Pr
Introduction :
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin.It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin.